Flavio Vincenti, M.D.
- Clinical Professor of Medicine and Surgery
- Departments of Medicine and Surgery
- Endowed Chair in Kidney Transplantation
Contact Information
Academic Office
(415) 353-8390
Fax: 415.353.8974
[email protected]
Appointments
(415) 353-1888 Liver
(415) 353-1551 Kidney and Pancreas
(415) 353-8390
Fax: 415.353.8974
[email protected]
Appointments
(415) 353-1888 Liver
(415) 353-1551 Kidney and Pancreas
Education
- American University Medical Center of Beirut, BS - 1971
- Universite Saint-Joseph Faculty of Medicine, MD - 1975
Fellowships
- Fellow in Nephrology, Emory University School of Medicine, Atlanta, Georgia, July 1, 1973 - June 30, 1975
- Research Fellow, National Kidney Foundation, July 1, 1974 - June 30, 1975
- Fellow in Cardiovascular Research Institute (Nephrology) University of California, San Francisco, July 1, 1975 - June 30, 1976
Biography
Dr. Flavio Vincenti, a kidney and pancreas transplant specialist, is board certified in internal medicine and nephrology. He came to UCSF Medical Center in 1975 for a transplant nephrology fellowship and was appointed a member of the kidney transplant team.
His memberships in professional organizations include the American Society of Nephrology, American Society of Transplantation, International Society of Nephrology and Transplantation Society. He is a co-leader of the kidney section of the Immune Tolerance Network for kidney transplantation. In addition, he is on the editorial board of the American Journal of Kidney Diseases and Graft.
In 1978, Vincenti was one of the authors of an article in the New England Journal of Medicine about the role of blood transfusions in improving kidney transplants. He also wrote a series of articles on the complications of transplants and has been a leading investigator and author on the use of anti interleukin 2 receptor monoclonal antibodies. In addition, he is a proponent of minimizing immunosuppressive drugs after transplants.
Research & Funding
Data provided by UCSF Profiles, powered by CTSI
ORCID iD: 0000-0002-6701-4680 
- Applying precision MEdicine to optimize desensitization with noveL bIOlogics or cellular theRApies in highly sensiTized kidney transplant patiEnts (AMELIORATE)Sponsor: NIHSponsor ID: U01AI113362Funding Period:Jul 2014-May 2024Principal Investigator
- Novel Therapies to Modulate the Inflammatory Alloresponse in Renal GraftsSponsor: NIH/NIAIDSponsor ID: U01AI113362Funding Period:Jul 2014-Jun 2021Principal Investigator
- General Clinical Research CenterSponsor: NIH/NCRRSponsor ID: M01RR000079Funding Period:Dec 1974-Mar 2009Co-Investigator
Clinical Trials
Data provided by UCSF Profiles, powered by CTSI
- Study ID: NCT04827979Start Date: Nov 2021Estimated Completion Date: Jun 2023Condition(s): Kidney Transplant
- Study ID: NCT04066114Start Date: Dec 2019Estimated Completion Date: Oct 2022Condition(s): Kidney Transplant
- Study ID: NCT03629080Start Date: Dec 2018Estimated Completion Date: Oct 2021Condition(s): Cytomegalovirus, Kidney Transplant
- Study ID: NCT03663335Start Date: Nov 2018Estimated Completion Date: Apr 2026Condition(s): Kidney Transplant
- Study ID: NCT03443869Start Date: May 2018Estimated Completion Date: Sep 2021Condition(s): Cytomegalovirus, Human Cytomegalovirus, Kidney Transplant
- Study ID: NCT03363945Start Date: Mar 2018Estimated Completion Date: Jan 2022Condition(s): Kidney Transplant, Immunotherapy
- Study ID: NCT02939365Start Date: Dec 2016Estimated Completion Date: Jun 2020Condition(s): Transplantation
- Study ID: NCT02711826Start Date: May 2016Estimated Completion Date: Oct 2021Condition(s): Kidney Transplant, Living Kidney Donor
- Study ID: NCT02474667Start Date: Mar 2016Estimated Completion Date: Dec 2021Condition(s): Delayed Graft Function
- Study ID: NCT02495077Start Date: Nov 2015Estimated Completion Date: Jun 2021Condition(s): Kidney Transplant
- Study ID: NCT03794817Start Date: Aug 2015Estimated Completion Date: Sep 2017Condition(s): Kidney Disease
- Study ID: NCT02108600Start Date: Jun 2014Estimated Completion Date: Dec 2018Condition(s): Kidney Transplant
- Study ID: NCT02088931Start Date: Mar 2014Estimated Completion Date: Dec 2016Condition(s): Kidney Transplant
- Study ID: NCT01974206Start Date: Nov 2013Estimated Completion Date: Nov 2020Condition(s): Cytomegalovirus, Kidney Transplant
- Study ID: NCT01771705Start Date: Apr 2013Estimated Completion Date: Jan 2017Condition(s): Kidney Transplant
- Study ID: NCT00777400Start Date: Dec 2008Estimated Completion Date: Apr 2009Condition(s): Autoimmune Disease
- Study ID: NCT00346151Start Date: Dec 2006Estimated Completion Date: Feb 2010Condition(s): Kidney Transplant
- Study ID: NCT00695097Start Date: Aug 2004Estimated Completion Date: Dec 2010Condition(s): Kidney Transplant
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 282
Data provided by UCSF Profiles, powered by CTSI
- Vincenti F, Angeletti A, Ghiggeri GM. State of the art in childhood nephrotic syndrome: concrete discoveries and unmet needs. Front Immunol. 2023; 14:1167741. View in PubMed
- Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, Stauffer N, Murata Y, Strizki JM, Teal VL, Gilbert CL, Haber BA. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA. 2023 07 03; 330(1):33-42. View in PubMed
- Duan M, Nguyen DC, Joyner CJ, Saney CL, Tipton CM, Andrews J, Lonial S, Kim C, Hentenaar I, Kosters A, Ghosn E, Jackson A, Knechtle S, Maruthamuthu S, Chandran S, Martin T, Rajalingam R, Vincenti F, Breeden C, Sanz I, Gibson G, Lee FE. Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses. Cell Rep. 2023 07 25; 42(7):112682. View in PubMed
- Vincenti F, Budde K, Grinyo J, Rostaing L, Kirk AD, Larsen CP. Open letter to Bristol Myers Squibb: Belatacept; we aren't done yet. Am J Transplant. 2023 10; 23(10):1483-1484. View in PubMed
- Raynaud M, Al-Awadhi S, Juric I, Divard G, Lombardi Y, Basic-Jukic N, Aubert O, Dubourg L, Masson I, Mariat C, Prié D, Pernin V, Le Quintrec M, Larson TS, Stegall MD, Bikbov B, Ruggenenti P, Mesnard L, Ibrahim HN, Nielsen MB, Matas AJ, Nankivell BJ, Benjamens S, Pol RA, Bakker SJL, Jouven X, Legendre C, Kamar N, Smith BH, Wadei HM, Durrbach A, Vincenti F, Remuzzi G, Lefaucheur C, Bentall AJ, Loupy A. Race-free estimated glomerular filtration rate equation in kidney transplant recipients: development and validation study. BMJ. 2023 05 31; 381:e073654. View in PubMed
- View All Publications
Videos
Data provided by UCSF Profiles, powered by CTSI
- Kidney Transplant Update - Donor Risks and Outcomes
- Management of Renal Failure in End Stage Liver Disease
- UCSF Kidney Transplant Update: Increasing the Donor Pool
- UCSF Kidney Transplant Update: Humoral Rejections; New Drugs
- UCSF Kidney Transplant Update: State of Transplantation, New Drugs, New Trials, Transplant Controversies
- UCSF Kidney Transplant Update 2011: State of Transplantation; Balance Between Efficacy and Toxicity at UCSF
In the News
- UCSF Transplant Surgery - January 28, 2016UCSF News reports on a clinical trial, BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial) where for the first time, an immunosuppressive agent, Belatacept, showed better organ survival in kidney transplant recipients than a calcineurin inhibitor, the current standard of care. The study was reported on in the January 28th issue of the New England Journal of Medicine by lead author, Flavio Vincenti, MD, Clinical Professor of Medicine and [...]
- UCSF Transplant Surgery - February 09, 2015The Contra Costa Times reports on the heartrending story of Chris Schroeder (pictured center), who received a donated kidney at age 50 from his wife, and then eight years later after the transplant failed, a second donated kidney from his son. Mr. Schroeder underwent successful surgery at UCSF Medical Center in December 2014 to have the transplanted kidney implanted. His UCSF nephrologist, Flavio Vincenti, M.D. said the rejection of the first kidney was "somewhat uncommon," and had been [...]
- UCSF Transplant Surgery - August 27, 2014Flavio Vincenti, M.D., UCSF Professor of Medicine and Surgery and a kidney and pancreas transplant specialist, is the principal investigator on a new seven-year, $17 million multicenter study funded by the National Institutes of Health. The goal of the study is to determine if certain immune system cells (regulatory T cells) and/or a drug used for treating rheumatoid arthritis can reduce or eliminate inflammation in kidney transplants thereby improving long-term health outcomes for kidney [...]
